Skip to main content
- News
Read a detailed conference report on our clinical tau modifier presented at AD/PD 2017

As a follow-up of our presentation at the 2017 AD/PD Conference in Vienna, please find here a detailed conference report on the latest clinical advances of tau modifiers including our clinical O-GlcNAcase inhibitor ASN120290:

"Treating Tau: Finally, Clinical Candidates Are Stepping into the Ring"

published on 27 April on



At the 13th International Conference on Alzheimer’s and Parkinson’s Diseases, held March 29 to April 2 in Vienna, Dr. Dirk Beher, CEO, presented preclinical data on its O-GlcNAcase inhibitor ASN120290 (previously ASN-561), which prevents tau tangles from forming. This compound has entered human clinical testing in healthy volunteers. 


Picture: Tau model mice treated for 3.5 months with an O-GlcNAcase inhibitor (right) develop few neurofibrillary tangles (black) compared to controls (left).
Source: Asceneuron